Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Table of contents
3. Section 1: introduction
4. Structure function of PE, DT and ricin
5. Immunotoxins
6. Background and objectives
7. Toxins used for preparation of immunotoxins
8. Mode of action of immunotoxins
9. Advantages: immunotoxins vs. naked antibodies
10. Disadvantages: immunotoxins vs. naked antibodies
11. Impediments in the application of immunotoxins
12. Section 2: anti-angiogenic therapy
13. Tumors at different stages of angiogenesis
14. Endoglin (CD105)
15. Reactivity of anti-EDG with endothelium (1)
16. Reactivity of anti-EDG with endothelium (2)
17. Cross-reactivity of anti-EDG with endothelium
18. Complete inhibition of MCF-7 in SCID mice
19. Section 3: a pretreatment strategy
20. Turnover time of various tissues
21. Blood clearance of IgG in BALB/c mice
22. Pharmacokinetic parameters of IgG in mice
23. Cumulative mouse mortality
24. Effect of pretreatment on mice weight
25. Effects of SN6f-dgRA / naked SN6f injections
26. LD50 values of SN6f-dgRA injected mice
27. Section 4: reducing immunogenicity
28. Strategies for minimizing immunogenicity
29. Section 5: immunotoxins versus naked mAbs
30. Anti-EDG: an anti-angiogenic therapy for tumors
31. Anti-EDG: a vascular targeting therapy for tumors
32. Prolonged complete suppression by SN7-RA
33. Therapy of SCID mice by SN7 and SN7-RA
34. Section 6: conclusions
35. Conclusions

Topics Covered

• Generation of immunotoxins
• Mode of action of different immunotoxins
• Strategies to overcome the major impediments in the therapeutic application of immunotoxins to cancer patients
• Anti-endoglin monoclonal antibodies and immunotoxins
• Anti-angiogenic therapy of tumors
• Vascular targeting therapy of tumors
• Comparison between immunotoxins and naked antibodies in therapeutic application

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Cancer
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Oncology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Ben Seon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.